Forlong Biotechnology

Based in Jiangsu, China, and founded in 2019, Suzhou Forlong Biotechnology Co. , Ltd. , trading as Forlong Biotechnology, is a clinical-stage biotechnology company focusing on the development of next-generation cytokine drugs. The company has established a clinical department and a R&D Department in Shanghai, China.

Its founder and CEO, Dr. Tianlei Ying, previously served as an investigator at the National Cancer Institute (NCI), USA. In September 2026, Forlong Biotechnology closed a round of Pre-series B funding led by Fosun Health Capital with participation from GF Xinde Investment, Detong Capital, Changshu Kaisheng Equity Investment Fund, Cambricon Technologies Corporation and Suzhou Chenfeng. Forlong Biotechnology has developed multiple drug pipelines for the treatment of cancer.

The company's core pipeline FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein that exerts anti-tumor effects by activating NK cells and memory T cells for treating non-muscle-invasive bladder cancer (NMIBC). Forlong Biotechnology also offers other pipelines such as FL117, FL118 and FL301 for the treatment of solid tumors. The company's revenue is generated by developing engineered therapeutic cytokine combinations that target different stages of the cancer-immune cycle to treat cancer. The company will primarily use the funding from Fosun Health Capital and other investors in September 2026 for advancing the pivotal Phase III clinical trial of FL115 for the treatment of non-muscle-invasive bladder cancer (NMIBC); conducting clinical trials for the subcutaneous formulation of FL115 in solid tumor indications; translating the latest breakthroughs from the fusion protein platform; and advancing FL116 (a PD-1/IL-18 bispecific antibody) into clinical trials for solid tumors.

The funding is also expected to support the company in team expansion, the upgrading and expansion of technology platforms, and the continued growth of the product pipeline.